Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.

Rink M, Schwarzenbach H, Riethdorf S, Soave A.

World J Urol. 2018 Oct 26. doi: 10.1007/s00345-018-2543-9. [Epub ahead of print]

PMID:
30367205
2.

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A.

Breast Cancer Res Treat. 2018 Oct 1. doi: 10.1007/s10549-018-4972-y. [Epub ahead of print]

PMID:
30276763
3.

Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer.

Woestemeier A, Ghadban T, Riethdorf S, Harms-Effenberger K, Konczalla L, Uzunoglu FG, Izbicki JR, Pantel K, Bockhorn M, Reeh M.

Anticancer Res. 2018 Oct;38(10):5665-5669. doi: 10.21873/anticanres.12902.

PMID:
30275185
4.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33041-7. doi: 10.1016/j.jtho.2018.08.2025. [Epub ahead of print] No abstract available.

PMID:
30205165
5.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.

Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, Fabre JM, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K.

Clin Chem. 2018 Oct;64(10):1505-1512. doi: 10.1373/clinchem.2018.289819. Epub 2018 Jul 20.

PMID:
30030273
6.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer EF, Fehm T, Müller V.

Breast Cancer Res Treat. 2018 Jul 12. doi: 10.1007/s10549-018-4882-z. [Epub ahead of print]

PMID:
30003393
7.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY.

Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211.

PMID:
29893791
8.

Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases.

Le UT, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi JT, Schmid S.

Sci Rep. 2018 Jun 8;8(1):8751. doi: 10.1038/s41598-018-26410-8.

9.

Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy."

Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M.

Urol Oncol. 2018 Jul;36(7):347-348. doi: 10.1016/j.urolonc.2018.05.013. Epub 2018 Jun 5.

PMID:
29880457
10.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.

Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching PA, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer EF, Witzel I, Müller V.

BMC Cancer. 2018 May 8;18(1):541. doi: 10.1186/s12885-018-4282-0.

11.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
12.

Clinical applications of the CellSearch platform in cancer patients.

Riethdorf S, O'Flaherty L, Hille C, Pantel K.

Adv Drug Deliv Rev. 2018 Feb 1;125:102-121. doi: 10.1016/j.addr.2018.01.011. Epub 2018 Feb 2. Review.

PMID:
29355669
13.

The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.

Riethdorf S, Soave A, Rink M.

Transl Androl Urol. 2017 Dec;6(6):1090-1110. doi: 10.21037/tau.2017.09.16. Review.

14.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells.

El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges TM, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P.

Clin Chem. 2018 Mar;64(3):536-546. doi: 10.1373/clinchem.2017.281295. Epub 2018 Jan 4.

PMID:
29301749
15.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Sci Rep. 2017 Dec 11;7(1):17307. doi: 10.1038/s41598-017-17514-8.

16.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.

von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H.

Oncotarget. 2017 Sep 23;8(52):89978-89987. doi: 10.18632/oncotarget.21208. eCollection 2017 Oct 27.

17.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.

Mohme M, Riethdorf S, Dreimann M, Werner S, Maire CL, Joosse SA, Bludau F, Mueller V, Neves RPL, Stoecklein NH, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker SO.

Sci Rep. 2017 Aug 3;7(1):7196. doi: 10.1038/s41598-017-07649-z.

18.

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.

Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Schem C, von Minckwitz G, Untch M, Pantel K.

Clin Cancer Res. 2017 Sep 15;23(18):5384-5393. doi: 10.1158/1078-0432.CCR-17-0255. Epub 2017 Jul 5.

19.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V.

Anticancer Res. 2017 Jun;37(6):3117-3128.

PMID:
28551653
20.

Catch and Release: rare cell analysis from a functionalised medical wire.

Chen S, El-Heliebi A, Tauber G, Langsenlehner T, Pötscher M, Kashofer K, Czyż ZT, Polzer B, Riethdorf S, Kuske A, Leitinger G, Pantel K, Kroneis T, Sedlmayr P.

Sci Rep. 2017 Feb 24;7:43424. doi: 10.1038/srep43424.

21.

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.

Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M.

BJU Int. 2017 Jun;119(6):854-861. doi: 10.1111/bju.13782. Epub 2017 Feb 9.

22.

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.

Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K.

Sci Rep. 2016 Dec 21;6:39736. doi: 10.1038/srep39736.

23.

Liquid biopsies for surveillance and monitoring treatment response of bladder cancer.

Riethdorf S, Pantel K.

Ann Transl Med. 2016 Oct;4(19):379. No abstract available.

24.

Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Mohme M, Riethdorf S, Pantel K.

Nat Rev Clin Oncol. 2017 Mar;14(3):155-167. doi: 10.1038/nrclinonc.2016.144. Epub 2016 Sep 20. Review.

PMID:
27644321
25.

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells.

Gorges TM, Kuske A, Röck K, Mauermann O, Müller V, Peine S, Verpoort K, Novosadova V, Kubista M, Riethdorf S, Pantel K.

Clin Chem. 2016 Nov;62(11):1504-1515. Epub 2016 Sep 14.

26.

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.

Deutsch TM, Riethdorf S, Nees J, Hartkopf AD, Schönfisch B, Domschke C, Sprick MR, Schütz F, Brucker SY, Stefanovic S, Sohn C, Pantel K, Trumpp A, Schneeweiss A, Wallwiener M.

Breast Cancer Res Treat. 2016 Nov;160(2):277-290. Epub 2016 Oct 1.

PMID:
27696083
27.

A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy.

Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M.

Int J Cancer. 2017 Jan 15;140(2):381-389. doi: 10.1002/ijc.30445. Epub 2016 Oct 11.

28.

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Gasch C, Oldopp T, Mauermann O, Gorges TM, Andreas A, Coith C, Müller V, Fehm T, Janni W, Pantel K, Riethdorf S.

Mol Oncol. 2016 Oct;10(8):1330-43. doi: 10.1016/j.molonc.2016.07.005. Epub 2016 Jul 22.

29.

Characterization of different CTC subpopulations in non-small cell lung cancer.

Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C, Stoecklein NH, Knoefel WT, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H.

Sci Rep. 2016 Jun 15;6:28010. doi: 10.1038/srep28010.

30.

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart M, Sotiriou C, Litiere S, Pierga JY.

Eur J Cancer. 2016 Aug;63:97-104. doi: 10.1016/j.ejca.2016.04.024. Epub 2016 Jun 10. Review.

PMID:
27289552
31.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.

Gorges TM, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse SA, Pantel K.

PLoS One. 2016 May 16;11(5):e0155126. doi: 10.1371/journal.pone.0155126. eCollection 2016.

32.

Plasma S100P level as a novel prognostic marker of metastatic breast cancer.

Peng C, Chen H, Wallwiener M, Modugno C, Cuk K, Madhavan D, Trumpp A, Heil J, Marmé F, Nees J, Riethdorf S, Schott S, Sohn C, Pantel K, Schneeweiss A, Yang R, Burwinkel B.

Breast Cancer Res Treat. 2016 Jun;157(2):329-338. doi: 10.1007/s10549-016-3776-1. Epub 2016 May 4.

PMID:
27146585
33.

Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.

Gorges TM, Riethdorf S, von Ahsen O, Nastał Y P, Röck K, Boede M, Peine S, Kuske A, Schmid E, Kneip C, König F, Rudolph M, Pantel K.

Oncotarget. 2016 Jun 7;7(23):34930-41. doi: 10.18632/oncotarget.9004.

34.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T.

Urol Oncol. 2016 May;34(5):235.e11-6. doi: 10.1016/j.urolonc.2015.12.003. Epub 2016 Jan 12.

PMID:
26795608
35.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells.

Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves RP, Stoecklein NH, Wikman H, Riethdorf S, Pantel K, Gorges TM.

Int J Cancer. 2016 Jun 15;138(12):2894-904. doi: 10.1002/ijc.30007. Epub 2016 Feb 26.

36.

Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis.

Madhavan D, Peng C, Wallwiener M, Zucknick M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, Sohn C, Chang-Claude J, Schneeweiss A, Burwinkel B.

Carcinogenesis. 2016 May;37(5):461-70. doi: 10.1093/carcin/bgw008. Epub 2016 Jan 19.

PMID:
26785733
37.

Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer.

Peng C, Wallwiener M, Rudolph A, Ćuk K, Eilber U, Celik M, Modugno C, Trumpp A, Heil J, Marmé F, Madhavan D, Nees J, Riethdorf S, Schott S, Sohn C, Pantel K, Schneeweiss A, Chang-Claude J, Yang R, Burwinkel B.

Int J Cancer. 2016 May 15;138(10):2499-509. doi: 10.1002/ijc.29975. Epub 2016 Feb 16.

38.

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.

Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Tucholski J, Lücke K, Wikman H, Jackson S, Brychta N, von Ahsen O, Schumann C, Krahn T, Pantel K.

Clin Cancer Res. 2016 May 1;22(9):2197-206. doi: 10.1158/1078-0432.CCR-15-1416. Epub 2015 Dec 14.

39.

Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response.

Bartkowiak K, Kwiatkowski M, Buck F, Gorges TM, Nilse L, Assmann V, Andreas A, Müller V, Wikman H, Riethdorf S, Schlüter H, Pantel K.

Cancer Res. 2015 Dec 15;75(24):5367-77. doi: 10.1158/0008-5472.CAN-14-3728. Epub 2015 Nov 16.

40.

Heterogeneity of miR-10b expression in circulating tumor cells.

Gasch C, Plummer PN, Jovanovic L, McInnes LM, Wescott D, Saunders CM, Schneeweiss A, Wallwiener M, Nelson C, Spring KJ, Riethdorf S, Thompson EW, Pantel K, Mellick AS.

Sci Rep. 2015 Nov 2;5:15980. doi: 10.1038/srep15980.

41.

A Versatile Microarray Platform for Capturing Rare Cells.

Brinkmann F, Hirtz M, Haller A, Gorges TM, Vellekoop MJ, Riethdorf S, Müller V, Pantel K, Fuchs H.

Sci Rep. 2015 Oct 23;5:15342. doi: 10.1038/srep15342.

42.

Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells.

Gasch C, Pantel K, Riethdorf S.

Methods Mol Biol. 2015;1347:221-32. doi: 10.1007/978-1-4939-2990-0_15.

PMID:
26374320
43.

Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues.

Riethdorf S, Frey S, Santjer S, Stoupiec M, Otto B, Riethdorf L, Koop C, Wilczak W, Simon R, Sauter G, Pantel K, Assmann V.

Int J Cancer. 2016 Feb 15;138(4):949-63. doi: 10.1002/ijc.29841. Epub 2015 Sep 25.

44.

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression.

Bednarz-Knoll N, Nastały P, Żaczek A, Stoupiec MG, Riethdorf S, Wikman H, Müller V, Skokowski J, Szade J, Sejda A, Wełnicka-Jaśkiewicz M, Pantel K.

Oncotarget. 2015 Sep 29;6(29):26789-803. doi: 10.18632/oncotarget.4628.

45.

Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?

Soave A, Riethdorf S, Pantel K, Fisch M, Rink M.

Curr Urol Rep. 2015 Jul;16(7):46. doi: 10.1007/s11934-015-0520-z. Review.

PMID:
26025496
46.

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.

Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B, Taran FA, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A.

BMC Cancer. 2015 May 14;15:403. doi: 10.1186/s12885-015-1423-6.

47.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.

Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefström J, Wilmanns M, Müller V, Pantel K, Wikman H.

Cancer Discov. 2015 May;5(5):506-19. doi: 10.1158/2159-8290.CD-14-1042. Epub 2015 Feb 25.

48.

Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer.

Reeh M, Effenberger KE, Koenig AM, Riethdorf S, Eichstädt D, Vettorazzi E, Uzunoglu FG, Vashist YK, Izbicki JR, Pantel K, Bockhorn M.

Ann Surg. 2015 Jun;261(6):1124-30. doi: 10.1097/SLA.0000000000001130.

PMID:
25607767
49.

Identification of HERC5 and its potential role in NSCLC progression.

Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effenberger K, Westphal M, Lamszus K, Kim SZ, Becker N, Izbicki JR, Sandoval J, Esteller M, Pantel K, Risch A, Wikman H.

Int J Cancer. 2015 May 15;136(10):2264-72. doi: 10.1002/ijc.29298. Epub 2014 Nov 9.

50.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR.

Breast Cancer Res. 2014 Aug 9;16(4):421. doi: 10.1186/s13058-014-0421-y.

Supplemental Content

Loading ...
Support Center